Beth Ashbridge is an associate in Goodwin’s Technology and Life Sciences group. Her practice focuses on commercialization of intellectual property rights, particularly in the life sciences and technology sectors. Goodwin’s Technology and Life Sciences group advises on transactions, including licenses, collaborations, distribution, manufacturing, outsourcing and R&D projects, as well as regulatory matters, contract and patent disputes, fundraisings, M&A transactions, and IPOs.
Beth also contributes to the firm's work in patent and commercial litigation, patent opinions and due diligence.
Beth joined Goodwin in 2013 as a Science Advisor and later qualified as a JD. Since 2013, Beth has been involved in several Hatch-Waxman and BPCIA patent litigation cases on both the brand and generic side. Beth is also an active contributor to the firm’s biosimilars blog, Big Molecule Watch, which is dedicated to providing resources and observations through Goodwin’s active watch of the world of biologics, biosimilars and the Biologics Price Competition and Innovation Act (BPCIA). Beth is an editor of Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., which provides expert guidance and practical know-how for lawyers working in this burgeoning area of the law. Beth is also a member of the firm’s specialist sectors: Late Stage Drug Development, FDA Litigation, and Life Science Disputes.
In 2019, Beth graduated from the JD part-time evening program at Fordham University School of Law with honors (cum laude), and was extended the Paul Fuller Scholar Designation.
Beth brings to her practice an exceptional combination of patent law expertise and technical proficiency in the pharmaceutical and biotechnology fields. Prior to joining Goodwin, Beth carried out her graduate research in the Chemical Biology program at the Department of Chemistry, University of Cambridge, under the supervision of Sir Professor Shankar Balasubramanian.
Following her graduate studies, Beth worked under the guidance of Dr. Malcolm A.S. Moore as a Research Fellow in the Cell Biology Program at Memorial Sloan-Kettering Cancer Center in New York City.
Fordham University School of Law
University of Cambridge
- New York
- Solicitor of the Senior Courts of England and Wales
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2022-2023 ed.,” published by Thomson Reuters, December 2022
- Special Contributor, Guide to Biosimilars Litigation and Regulation in the U.S., 2020-2021 ed., published by Thomson Reuters, January 2021
- Speaker, “Clinical Trials, Marketing, and Labeling: Strategies for Proving and Defending Induced Infringement of Biosimilars,” Webinar, October 2020
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, November 2019
- Speaker, “What Can You Be with a PHD?: A Science & Technology Career Symposium in Partnership with Springer Nature,” October 2019